argenex (ARGX) Competitors

Sanofi (NASDAQ:SNY) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Which has higher valuation & earnings, SNY or ARGX?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.46B	2.75	$6.02B	$4.16	11.96
argenex	$3.05B	13.11	$833.04M	$19.50	33.53

Do institutionals & insiders believe in SNY or ARGX?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is SNY or ARGX more profitable?

argenex has a net margin of 40.98% compared to Sanofi's net margin of 21.47%. argenex's return on equity of 21.06% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	21.47%	16.86%	9.63%
argenex	40.98%	21.06%	18.25%

Which has more risk & volatility, SNY or ARGX?

Sanofi has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Do analysts rate SNY or ARGX?

Sanofi presently has a consensus price target of $62.00, indicating a potential upside of 24.57%. argenex has a consensus price target of $746.81, indicating a potential upside of 14.22%. Given Sanofi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sanofi is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11
argenex	0 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.10

Does the media refer more to SNY or ARGX?

In the previous week, Sanofi had 9 more articles in the media than argenex. MarketBeat recorded 27 mentions for Sanofi and 18 mentions for argenex. argenex's average media sentiment score of 1.27 beat Sanofi's score of 0.98 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	10 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	11 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Sanofi on 10 of the 17 factors compared between the two stocks.